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In this issue of Annals of Surgical Oncology, Kroon et al.
describe the toxicity of isolated limb infusion with melphalan
and actinomycin D in their experience with 185 patients over
15 years.1 This work continues to expand on the group’s
notable contributions to regional chemotherapeutics for
extremity melanoma including their initial description and
utilization of isolated limb infusion (ILI) in the early 1990s.2
ILI has been explored as a minimally invasive alternative to
hyperthermic isolated limb perfusion (HILP) for advanced
extremity melanoma whereby placement of percutaneously
placed catheters allows delivery of regional chemotherapy to
an isolated limb. In the current study, ILI was found to be a
safe alternative to HILP with less long-term morbidity than
HILP. Previously, the Sydney Melanoma Group has reported
response rates that are less than traditional response rates to
HILP but certainly not outside the range of reported studies
of HILP.3 Due to the safety and efficacy of the treatment as
well as disappointing results of a multicenter HILP trial,4 ILI
is now utilized at several major US centers and has been
demonstrated to be a well-tolerated treatment alternative for
patients with advanced extremity melanoma.5,6
As with any new regional treatment, the goal should be
to define the procedure’s therapeutic index, which balances
the treatment’s toxicity with its ability to control disease.
Results of the current study suggest that there may be
additional methods to reduce toxicity from ILI by altering
modifiable factors which were found to be predictive of
higher grades of toxicity. In addition this study’s results
further support a role for ILI as a safe treatment in the
armamentarium of therapeutic options for patients with
advanced extremity melanoma.
ILI is essentially a low-flow HILP performed by inser-
tion of percutaneous catheters in the contralateral limb, in
contrast to HILP where open surgical cannulation of the
artery and vein are performed. ILI is performed attempting
to achieve temperatures in the range 37–38.5C and the
blood is not oxygenated, leading to hypoxia and acidosis in
the limb. The hypoxia and acidosis of ILI have previously
been suggested to be beneficial in terms of response.7 In
HILP, the catheters are connected to a cardiopulmonary
bypass circuit which maintains physiologic oxygenation
and pH. Temperatures in HILP generally range from
38.5C to 40C. While hyperthermia is well documented to
increase the cytotoxicity induced by melphalan,8 excessive
heat can also increase the toxicity of melphalan to normal
tissue. ILI also differs from HILP in that ILI uses less
melphalan per liter of extremity treated, circulates blood in
an isolated extremity at a much slower rate than HILP (50–
100 mL/min in ILI7 versus 350–1,000 mL/min in HILP9),
and treatment is only for 30 min as compared with 60 min
in HILP. These differences in the method of drug delivery
are important to consider when comparing toxicity and
response between the two procedures.
In both ILI and HILP, there appears to be no relationship
between significant limb toxicity and response to treat-
ment.7,10,11 As such, minimizing toxicity from these
procedures as discussed by the authors should be a goal of
therapy. In the current study, high-grade limb toxicity
(Wiberdink toxicity C grade 3) occurred in 42% (n = 77)
of patients. Only 3% (n = 5) of patients had grade IV
toxicities and there were no grade V toxicities (grade V
toxicity is a toxicity necessitating amputation). Systemic
toxicities were minimal and melphalan was detected in the
systemic circulation in only 6% of patients. There were no
systemic effects clearly associated with leakage of the
small amounts of melphalan into the systemic circulation.
Low circulating volumes seen in ILI were not related to
increased limb toxicity. Overall toxicity from this study is
in a similar range to the spectrum of toxicity after HILP.
However, as the authors point out, long-term morbidity and
severe toxicity (grade V) appear to be less with ILI. In a
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retrospective comparison of patients undergoing HILP and
ILI at Duke University, patients undergoing ILI had sig-
nificantly less toxicity than those undergoing HILP.5 In a
recent retrospective US multicenter study of ILI, there was
one treatment-associated amputation in 162 patients.11
Analysis of data from the SMU, Duke University, MD
Anderson Cancer Center, and other centers performing ILI
in the USA demonstrated the rate of toxicity necessitating
amputation to be approximately five- to tenfold less in
patients undergoing ILI compared with HILP (0.2–0.3% in
ILI versus 1–2% in HILP).10 The results of the current
study are thus in accordance with other reports and suggest
that ILI can be performed safely with less severe and less
long-term morbidity than HILP.
The authors performed a detailed analysis of factors that
might predict toxicity, which may be important in mini-
mizing toxicity from ILI. Interestingly, on univariate
analysis the authors found high peak and high final mel-
phalan concentrations as well as increased serum creatine
phosphokinase (CK) postoperatively to be predictive of
grade III/IV toxicity. In addition, on multivariate analysis
both higher melphalan concentration and shorter tourniquet
time were independent factors for developing grade III/IV
toxicity. Higher peak melphalan concentration has shown
to be predictive of toxicity in HILP12 while higher mel-
phalan dose has been associated with increased toxicity in a
multicenter study of ILI.5 Based on pharmacokinetic
analysis at our own institution,13,14 which demonstrated
wide variability in melphalan concentration in patients
undergoing ILI, we began modifying the melphalan dose
for ideal body weight (IBW).11 In both our series of ILI and
in a recent multicenter study of ILI, correction of the
melphalan dose for IBW significantly reduced toxicity
without altering complete response rates. In a similar
fashion, a melphalan dose corrected for IBW was also
found to be associated with significantly lower postopera-
tive peak CK levels in those two studies.5,11 Consistent
with the SMU data, the recent multi-institutional study of
ILI also found higher peak CK to be significantly associ-
ated with higher grades of toxicity. Correction of the
melphalan dose for IBW is thus a method of lowering the
melphalan dose which successfully decreases postoperative
CK values and minimizes limb toxicity without altering
complete response (CR) rates. This dosing modification
also appears to decrease toxicity in HILP without altering
CR rates.13
In addition to minimizing toxicity, another goal of
regional therapy is to maximize the complete response rate.
Complete responses are the most important outcome
measurement with the greatest potential therapeutic benefit
as most patients with partial responses, stable disease, or
progressive disease require additional treatment. While
dose reductions seem to decrease overall response rates, no
difference in CR rates have been noted. Additional strate-
gies to increase CR rates have recently been explored; for
example, a recent phase I trial using the targeted agent
ADH-1, which disrupts N-cadherin binding, was associated
with a 50% CR rate when given systemically 6–10 h before
melphalan-based treatment.14,15 The multicenter phase II
trial of systemic ADH-1 and regional ILI has completed
accrual and is currently under analysis. Other targeted
compounds currently in phase I trials being studied for
their ability to increase CR rates include Sorafenib and
buthionine sulfoximine (BSO), which are given systemi-
cally in combination with ILI treatment.
While the exact place of ILI in managing regionally
advanced disease remains to be determined, the work of the
SMU group, which is now being replicated in other centers
in the USA, would argue that ILI might be the best initial
therapy given its low toxicity and approximate 30–40% CR
rate. Patients who fail ILI could then be treated with HILP,
repeat ILI, or protocol-based ILI. One challenge for the
regional chemotherapy group of surgeons is to utilize
studies such as the current one to define the current ‘‘stan-
dard’’ approach to ILI in an attempt to establish a consensus
statement or methodology on the treatment variables asso-
ciated with the procedure. Achieving agreement on such
variables as melphalan dosing, target tourniquet times,
response determinations, and use of papaverine would not
only allow for more uniform implementation of the therapy
but would also help develop a basis upon which incremental
advances could more readily be achieved.
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